<DOC>
	<DOCNO>NCT00395473</DOCNO>
	<brief_summary>In context australian general practice , determine efficacy safety ezetimibe 10mg/statin 40mg coadministration patient uncontrolled cholesterol receive statin 40mg .</brief_summary>
	<brief_title>Ezetimibe Added Statin Therapy ( EASY ) Study ( 0653-087 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Patients remain stable statin dose 40mg , duration study Patients coronary heart disease diabetes mellitus whose cholesterol level remain initial threshold government subsidy least 3 month treatment daily dose 40mg great statin Illnesses congestive heart failure nyha class iii iv Uncontrolled hypertension Myocardial infarction Coronary bypass surgery angioplasty without stent within 3 month enrolment visit Unstable angina pectoris unstable severe peripheral vascular disease Uncontrolled endocrine metabolic disease know influence serum lipid lipoprotein , ex : type type ii diabetes mellitus poorly control Serum creatinine &gt; 0.18mmol/l enrolment active renal disease significant proteinuria Disorders haematologic , digestive ( include malabsorptive disorder ) Central nervous system include cerebrovascular disease degenerative disease would limit study evaluation participation Active acute chronic hepatobiliary disease Patients take following medication : medication know interact statin medication include antifungal azoles , macrolide antibiotic , telithromycin ; nefazodone ; protease inhibitor ; amiodarone ; danazol verapamil ; fibrates ; cyclosporin Tg &gt; 4.0mmol/l use statin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>